Mielóma multiplex: vizsgálatok itt: Norvégia
32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Oslo, Trondheim
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Loerenskog, Oslo, Stavanger, Trondheim
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Oslo
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 1/2. fázisTaking peopleA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Where
- Oslo
- Életkor
- 18 év to 64 év
- People
- 602 worldwide
- Run by
- AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00 - 2/3. fázisTaking peopleA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00 - No phaseNot yet taking people in NorvégiaImmunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Odense University Hospital
See details and how to joinNCT07878208 - 1/2. fázisTaking peopleIsatuximab in Combination With Novel Agents in RRMM - Master Protocol
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 258 worldwide
- Run by
- Sanofi
See details and how to joinNCT04643002 - 3. fázisTaking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Levanger, Loerenskog, Oslo, Trondheim
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - 3. fázisNot yet taking people in NorvégiaA trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-525367-40-00 · EU 2026-525367-40-00 - 3. fázisTaking peopleA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657 - 1/2. fázisTaking peopleA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Where
- Oslo, Trondheim
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00 - No phaseTaking peopleA Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
- Where
- Oslo, Tønsberg
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Janssen-Cilag Ltd.
See details and how to joinNCT06285318 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Bergen, Oslo, Stavanger, Trondheim
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - 3. fázisTaking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Loerenskog, Oslo, Tonsberg, Trondheim
- Életkor
- 18 év and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - 2. fázisNot yet taking people in NorvégiaTeclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
- Where
- Oslo, Stavanger, Tønsberg, Trondheim
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Odense University Hospital
See details and how to joinNCT07757412 · EU 2025-522114-23-00 - 3. fázisTaking peopleA trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 153 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-523285-25-00 · EU 2025-523285-25-00 - 2. fázisTaking peopleA multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 105 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to join2023-505775-70-00 · EU 2023-505775-70-00 - 3. fázisNot yet taking people in NorvégiaA Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- Where
- Bergen
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00 - No phaseTaking peopleThe Norwegian Immunotherapy in Multiple Myeloma Study
- Where
- Ålesund, Arendal, Bærum, Bergen, Bodø, Drammen, Førde, Gjøvik, Haugesund, Kristiansand, Kristiansund, Levanger, Molde, Nordbyhagen, Oslo, Skien, Stavanger, Tønsberg, Tromsø, Trondheim, Volda
- Életkor
- 18 év and over
- People
- 400
- Run by
- St. Olavs Hospital
See details and how to joinNCT06855121 - 1. fázisTaking peopleStudy of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 135 worldwide
- Run by
- AbbVie
See details and how to joinNCT06896916 · EU 2024-512146-41-00 - 3. fázisTaking peopleA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Aalesund, Bergen, Lørenskog, Oslo
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - 2. fázisTaking peopleStudy for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- Where
- Oslo, Toensberg
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT07107529 · EU 2024-520433-76-00 - 1. fázisTaking peopleStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Ichnos Sciences SA
See details and how to joinNCT05862012 · EU 2023-507071-21-01